2009-2007年 研究業績
2019- 2018-2016 2015-2013 2012-2010 2006-2004 2003-2001 2000以前
1) Toba T, Murata K, Nakanishi K, Takahashi B, Takemoto N, Akabane M, Nakatsuka T, Imajo S, Yamamura T, Miyake S
and Annoura H: Minimum structure requirement of immunomodulatory
glycolipids for predominant Th2 cytokine induction and the discovery of
non-linear phytosphingosine analogs. Bioorganic Med Chem Let 17:2781-2784, 2007
2) Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S: Activation of iNKT cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis Rheum 56:1836-1845, 2007
3) Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T: Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 179:3452-3462, 2007
4) Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S,
Yamamura T, Kumar V, Berzofskky: Cross-regulation between Type I and
Type II NKT cells in regulating turmor immunity: A new immunoregulatory
axis. J Immunol 179:5126-5136, 2007
5) Oki S, Miyake S:
Invariant Natural Killer T (iNKT) cells in asthma: A novel insight into
the pathogenesis of asthma and the therapeutic implication of
glycolipid ligands for allergic diseases. Allergol Int 56:7-14, 2007
6) Miyake S, Yamamura T: Therapeutic potential of CD1d-restriced invariant natural killer T cell-based treatment for autoimmune diseases. Int Rev Immunol 26:73-94, 2007
7) Miyake S, Yamamura T: NKT cells and autoimmune diseases: unrabeling the complexity. Cur Top Microbiol Immunol 314:251-267, 2007
8) Yamamura T, Sakuishi K, Illes Z, Miyake S: Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 1914:8-15, 2007
9) Miyake S, Yamamura T: NKT cells and Autoimmune Diseases: Unraveling the complexity. Current Topics in Microbiology and Immunology Moody DB, ed, Springer-Verlag, Heidelberg, 251-65 2007
10) Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, Miyake S,
Yammaura T, McMahon-Pratt D: Intradermal NKT cell activation during DNA
priming in heterologous prime-boost vaccination enhances T cell
responses and protection against Leishmania. Eur J Immunol 38:706-19, 2008
11) Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S,
Yamamura T: Orphan nuclear receptor NR4A2 expressed in T cells from
multiple sclerosis mediates production of inflammatory cytokines. Proc Natl Acad Sci USA 105:8381-8386, 2008
12) Sekine C, Sugihara T, Miyake S,
Hirai H, Yoshida M, Miyasaka N, Kohsaka H: Successful treatment of
animal models of rheumatoid arthritis with small-molecule
cyclin-dependent kinase inhibitors. J Immunol 180:1954-1961, 2008
13) Yokote H, Miyake S,
Croxford JL, Oki S, Mizusawa H, Yamamura T: NKT cell-dependent
amelioration of a mouse model of multiple sclerosis by altering gut
flora. Ame J Patho 173:1714-23, 2008
14) Okamoto T, Ogawa M, Lin Y, Murata M, Miyake S, Yamamura T: Treatment of neuromyelitis optica: Current debate. Therapeutic Advances Neurol 1 (1):43-52, 2008
15) Araki M, Miyake S, Yamamura T: Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. Curr Med Chem 15(23):2337-2345, 2008
16) Theil MM, Miyake S,
Mizuno M, Tomi C, Croxford J, Hosoda H, Theil J, von Horsten S, Yokote
H, Chiba A, Lin Y, Oki S, Akamizu T, Kanagawa K, Yamamura T:
Suppression of experimental autoimmune encephalomyelitis by Ghrelin. J Immunol. 83(4):2859-66, 2009
17) Fujita M, Otsuka T, Mizuno M, Tomi C, Yamamura T, Miyake S:
Carcinoembryonic antigen-related cell adhesion molecule 1 modulates
experimental autoimmune encephalomyelitis via iNKT cell-dependent
mechanism. Ame J Patho 175(3):1116-23, 2009
18) Miyake S, Yamamura T. Ghrelin: friend or foe for neuroinflammation. Deicov Med 8(41):64-67, 2009
順天堂大学医学部 順天堂大学大学院医学研究科
〒113-8421 東京都文京区本郷2-1-1 新研究棟（7号館）6階 6Nスタッフルーム
電話：03-5802-1044／1045 FAX：03-3813-0421